CanSino Biologics Inc. is joining other Hong Kong-listed biotechnology companies in seeking to list on Shanghai’s Star Board, just six months after going public in the financial hub that is now roiled by protests.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
